ClinicalTrials.gg
CompletedNCT04531462Updated May 2, 2024Results posted

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

A Phase 4 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 18 sites in Japan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
47th of 130
129 · median 79
Started
2020
with 12 others
Phase 4
50 of 130
11 open now
Registered
82nd of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 47th largest by enrollment, is one of 13 that started in 2020, is one of 50 in phase 4, and was the 82nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition compared to placebo in elderly patients with T2DM.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese (defined as patient has parents who are Japanese) patients with diagnosis of Type 2 diabetes mellitus (T2DM) prior to
  • (HbA1c) ≥7.0% and ≤10.0% for patients at Visit 1 (screening). If the patient is on treatment with oral antidiabetic drug(s) potentially associated with severe hypoglycaemia (e.g., sulfonylurea or glinides), the following HbA1c value is used as criterion

    • HbA1c ≥7.5% and ≤10.0% for age ≥65 and \<75
    • HbA1c ≥8.0% and ≤10.0% for age ≥75
  • Patients on diet and exercise regimen who are drug-naïve (drug-naïve is defined as no antidiabetic drugs for at least 12 weeks prior to informed consent) or on treatment with any oral antidiabetic drug (OAD) other than Glucagon-Like Peptide-1 (GLP-1) agonists and Sodium-glucose cotransporter 2 (SGLT-2) inhibitor. Antidiabetic therapy has to be unchanged for 12 weeks prior to randomisation (any thiazolidinedione therapy has to be unchanged for at least 18 weeks prior to informed consent).
  • Age ≥65 years at informed consent
  • ≥22 kg/m2 at Visit 1 (screening)
  • Male or (a point in time 12 months after a woman's last period) female patients
  • Patient signed and dated written informed consent in accordance with International Conference on Harmonization (ICH)- Good Clinical Practice (GCP) and local legislation prior to admission to the Trial

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hyperglycaemia with a fasting glucose level >200 milligram per deciliter (mg/dL) (>11.1 millimol per Liter (mmol/L)) during run-in period
  • Treatment with insulin within 12 weeks prior to
  • Impaired cognitive ability as supported by (MMSE-J, defined as ≤23) and verified by the investigator at screening
  • Acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI, and unstable angina pectoris), stroke or within 12 weeks prior to informed consent
  • Indication of liver disease, defined by serum levels of either (ALT = serum glutamic-pyruvic transaminase [SGPT]), aspartate aminotransferase (AST = serum glutamic-oxaloacetic transaminase[SGOT]), or alkaline phosphatase (ALP) above 3 x (ULN) as determined during screening and run-in period
  • Impaired renal function, defined as Estimated (eGFR) \<45 milliliter per minute per 1.73 square meter (mL/min/1.73 m2, severe renal impairment, Modification of Diet in Renal Disease (MDRD) formula) as determined during screening and run-in period
  • Low grip strength defined as \<28 kilogram (kg) for male or as \<18 kg for female at screening
  • Short length of calf circumference defined as \<34 centimeter (cm) for male or 33 cm for female at screening
  • further exclusion criteria apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Empagliflozin 10 mg

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline After 52 Weeks of Treatment

    Change in glycated hemoglobin (HbA1c) (in units of %) from baseline after 52 weeks of treatment was modelled using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) which included fixed classification effects for treatment, gender, baseline renal function, visit and visit-by-treatment interaction, and a linear covariate for baseline HbA1c and age. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.The Least Squares Mean (Standard Error) after 52 weeks of treatment is reported.

    Time frame: Change in HbA1c from baseline after 52 weeks of treatment was calculated using the MMRM model which is a longitudinal analyses and it incorporates HbA1c values from baseline and after 4 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks of treatment.

Secondary outcomes

  1. Change of Muscle Mass From Baseline to Week 52

    Muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of muscle mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline muscle mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52

  2. Change of Body Fat Measurement From Baseline to Week 52

    Body fat mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of body fat measurement from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline body fat measurement, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52

  3. Change of Lean Body Mass From Baseline to Week 52

    Lean body mass (fat-free mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of lean body mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline lean body mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52.

  4. Change of Total Body Water From Baseline to Week 52

    Total body water was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of total body water from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline total body water, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52.

  5. Change of Bone Mineral Content From Baseline to Week 52

    Bone mineral content (estimated bone mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of bone mineral content from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline bone mineral content, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52.

  6. Change of Skeletal Muscle Index From Baseline to Week 52

    Skeletal muscle index is calculated by dividing the limb muscle mass (kg) by the square of the height (m2). The limb muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of skeletal muscle index from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline skeletal muscle index, age, baseline glycated hemoglobin (HbA1c), baseline body mass index as linear covariates and sex, treatment as fixed effects. "Baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52.

  7. Change of Grip Strength From Baseline to Week 52

    A Smedley-type dynamometer was used to measure grip strength. The site staff instructed the patient to adjust the grip width so that the second joint of the index finger is approximately 90 degrees (almost right angle). The site staff asked the patient to be careful not to touch the body or clothes with hand while keeping arms down naturally. The site staff made sure that the patient does not wave the grip dynamometer. Grip strength was measured twice alternately left and right. Change of grip strength from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline grip strength, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52.

  8. Change of Time in the 5-time Chair Stand Test From Baseline to Week 52

    For the stand test patients fold their arms across their chest and try to stand up once from a chair. If patients can stand from a chair, they repeat same action five times. It is measured the time required to perform five rise from a chair to an upright position as fast as possible without the use of arms. Change of time in the 5-time chair stand test from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline 5-time chair stand test, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

    Time frame: At baseline and at Week 52.

07

Results

Posted Mar 12, 2024

Participant flow

This randomised, double-blind, placebo-controlled, parallel group, multicentre trial compared 10 mg empagliflozin with placebo after 52 weeks in elderly Japanese patients with Type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 10 mg
Started6465
Completed5861
Not completed64
Withdrew: Withdrawal by subject31
Withdrew: Adverse event33

Outcome measures

PrimaryChange in HbA1c From Baseline After 52 Weeks of Treatment

Change in glycated hemoglobin (HbA1c) (in units of %) from baseline after 52 weeks of treatment was modelled using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) which included fixed classification effects for treatment, gender, baseline renal function, visit and visit-by-treatment interaction, and a linear covariate for baseline HbA1c and age. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.The Least Squares Mean (Standard Error) after 52 weeks of treatment is reported.

Time frame:
Change in HbA1c from baseline after 52 weeks of treatment was calculated using the MMRM model which is a longitudinal analyses and it incorporates HbA1c values from baseline and after 4 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks of treatment.
Reported as:
Least squares mean · percentage of glycated hemoglobin
Change in HbA1c From Baseline After 52 Weeks of Treatment
percentage of glycated hemoglobinPlaceboEmpagliflozin 10 mg
Change in HbA1c From Baseline After 52 Weeks of Treatment-0.12 ± 0.08-0.69 ± 0.07
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed Model Repeated Measures (MMRM) · p = <0.0001 (Threshold level for statistical significance: α = 0.05 .) · Mean difference (net): -0.57 · 95% CI -0.78 to -0.36Empagliflozin 10 mg- Placebo
SecondaryChange of Muscle Mass From Baseline to Week 52

Muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of muscle mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline muscle mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52
Reported as:
Least squares mean · kilogram
Change of Muscle Mass From Baseline to Week 52
kilogramPlaceboEmpagliflozin 10 mg
Change of Muscle Mass From Baseline to Week 52-0.96 ± 0.36-1.57 ± 0.35
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.2310 · Mean difference (net): -0.61 · 95% CI -1.61 to 0.39Empagliflozin 10 mg- Placebo
SecondaryChange of Body Fat Measurement From Baseline to Week 52

Body fat mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of body fat measurement from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline body fat measurement, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52
Reported as:
Least squares mean · kilogram
Change of Body Fat Measurement From Baseline to Week 52
kilogramPlaceboEmpagliflozin 10 mg
Change of Body Fat Measurement From Baseline to Week 520.08 ± 0.29-1.77 ± 0.28
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Mean difference (net): -1.84 · 95% CI -2.65 to -1.04Empagliflozin 10 mg- Placebo
SecondaryChange of Lean Body Mass From Baseline to Week 52

Lean body mass (fat-free mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of lean body mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline lean body mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52.
Reported as:
Least squares mean · kilogram
Change of Lean Body Mass From Baseline to Week 52
kilogramPlaceboEmpagliflozin 10 mg
Change of Lean Body Mass From Baseline to Week 52-1.08 ± 0.27-1.61 ± 0.26
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.1632 · Mean difference (net): -0.53 · 95% CI -1.28 to 0.22Empagliflozin 10 mg- Placebo
SecondaryChange of Total Body Water From Baseline to Week 52

Total body water was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of total body water from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline total body water, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52.
Reported as:
Least squares mean · kilogram
Change of Total Body Water From Baseline to Week 52
kilogramPlaceboEmpagliflozin 10 mg
Change of Total Body Water From Baseline to Week 52-0.72 ± 0.21-1.35 ± 0.21
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.0384 · Mean difference (net): -0.63 · 95% CI -1.23 to -0.03Empagliflozin 10 mg- Placebo
SecondaryChange of Bone Mineral Content From Baseline to Week 52

Bone mineral content (estimated bone mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of bone mineral content from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline bone mineral content, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52.
Reported as:
Least squares mean · kilogram
Change of Bone Mineral Content From Baseline to Week 52
kilogramPlaceboEmpagliflozin 10 mg
Change of Bone Mineral Content From Baseline to Week 52-0.06 ± 0.02-0.09 ± 0.01
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.1975 · Mean difference (net): -0.03 · 95% CI -0.07 to 0.01Empagliflozin 10 mg- Placebo
SecondaryChange of Skeletal Muscle Index From Baseline to Week 52

Skeletal muscle index is calculated by dividing the limb muscle mass (kg) by the square of the height (m2). The limb muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of skeletal muscle index from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline skeletal muscle index, age, baseline glycated hemoglobin (HbA1c), baseline body mass index as linear covariates and sex, treatment as fixed effects. "Baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52.
Reported as:
Least squares mean · kilogram/meter^2 (kg/m^2)
Change of Skeletal Muscle Index From Baseline to Week 52
kilogram/meter^2 (kg/m^2)PlaceboEmpagliflozin 10 mg
Change of Skeletal Muscle Index From Baseline to Week 52-0.245 ± 0.064-0.326 ± 0.062
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.3725 · Mean difference (net): -0.081 · 95% CI -0.259 to 0.098Empagliflozin 10 mg- Placebo
SecondaryChange of Grip Strength From Baseline to Week 52

A Smedley-type dynamometer was used to measure grip strength. The site staff instructed the patient to adjust the grip width so that the second joint of the index finger is approximately 90 degrees (almost right angle). The site staff asked the patient to be careful not to touch the body or clothes with hand while keeping arms down naturally. The site staff made sure that the patient does not wave the grip dynamometer. Grip strength was measured twice alternately left and right. Change of grip strength from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline grip strength, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52.
Reported as:
Least squares mean · kilogram
Change of Grip Strength From Baseline to Week 52
kilogramPlaceboEmpagliflozin 10 mg
Change of Grip Strength From Baseline to Week 52-0.6 ± 0.3-0.9 ± 0.3
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.4208 · Mean difference (net): -0.3 · 95% CI -1.1 to 0.5Empagliflozin 10 mg- Placebo
SecondaryChange of Time in the 5-time Chair Stand Test From Baseline to Week 52

For the stand test patients fold their arms across their chest and try to stand up once from a chair. If patients can stand from a chair, they repeat same action five times. It is measured the time required to perform five rise from a chair to an upright position as fast as possible without the use of arms. Change of time in the 5-time chair stand test from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline 5-time chair stand test, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.

Time frame:
At baseline and at Week 52.
Reported as:
Least squares mean · seconds
Change of Time in the 5-time Chair Stand Test From Baseline to Week 52
secondsPlaceboEmpagliflozin 10 mg
Change of Time in the 5-time Chair Stand Test From Baseline to Week 52-0.9 ± 0.3-0.9 ± 0.3
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = 0.9267 · Mean difference (net): 0.0 · 95% CI -1.0 to 0.9Empagliflozin 10 mg- Placebo

Adverse events

Collected over From the administration of first dose of randomised trial medication until treatment stop +7 days of residual effect period, up to 378 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/64 (1.6%)8/64 (12.5%)13/64 (20.3%)
Empagliflozin 10mg0/65 (0%)8/65 (12.3%)14/65 (21.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboEmpagliflozin 10mg
Femoral neck fractureInjury, poisoning and procedural complications2/640/65
CataractEye disorders1/641/65
DeathGeneral disorders1/640/65
Brain contusionInjury, poisoning and procedural complications1/640/65
Rib fractureInjury, poisoning and procedural complications1/640/65
Traumatic haemothoraxInjury, poisoning and procedural complications1/640/65
Facial paralysisNervous system disorders1/640/65
Optic neuritisNervous system disorders1/640/65
Atrial fibrillationCardiac disorders0/641/65
Exfoliation glaucomaEye disorders0/641/65
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10mg
ConstipationGastrointestinal disorders3/647/65
DiarrhoeaGastrointestinal disorders4/640/65
NasopharyngitisInfections and infestations4/643/65
PyrexiaGeneral disorders3/644/65

Baseline characteristics

Full Analysis Set (FAS): This set included all patients randomised, treated with at least one dose of trial medication, and with a baseline and at least one on-treatment glycated haemoglobin (HbA1c) value.

Age, Continuous
Age, Continuous(years)PlaceboEmpagliflozin 10 mgTotal
Mean74.0 ± 5.174.2 ± 4.974.1 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 10 mgTotal
Female191635
Male444892
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 mgTotal
Hispanic or Latino000
Not Hispanic or Latino6364127
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 mgTotal
American Indian or Alaska Native000
Asian6364127
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Percentage of glycated haemoglobin (HbA1c)
Percentage of glycated haemoglobin (HbA1c)(Percentage of glycated haemoglobin)PlaceboEmpagliflozin 10 mgTotal
Mean7.6 ± 0.57.6 ± 0.57.6 ± 0.5
08

Study locations

18 sites
  • Meitetsu Hospital
    Aichi, Nagoya, 451-8511, Japan
  • Chubu Rosai Hospital
    Aichi, Nagoya, 455-8530, Japan
  • Daido Hospital
    Aichi, Nagoya, 457-8511, Japan
  • Seino Internal Medicine Clinic
    Fukushima, Koriyama, 963-8851, Japan
  • Gifu University Hospital
    Gifu, Gifu, 501-1194, Japan
  • Watanabe Clinic
    Hyogo, Nishinomiya, 662-0971, Japan
  • Institute Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic
    Kanagawa, Yokohama, 231-0023, Japan
  • Medical Corporation KEISEIKAI Kajiyama Clinic
    Kyoto, Kyoto, 600-8898, Japan
  • Medical Corporation Hayashi Katagihara Clinic
    Kyoto, Kyoto, 615-8125, Japan
  • Iryouhouijneiwakai Minamiakatsuka Clinic
    Mito, Ibaraki, 311-4153, Japan
  • Moriya Keiyu Hospital
    Moriya, Ibaraki, 302-0118, Japan
  • North Alps Medical Center Azumi Hospital
    Nagano, Kitaazumi-gun, 399-8695, Japan
  • Asama Nanroku Komoro Medical Center
    Nagano, Komoro, 384-8588, Japan
  • Koshigaya Municipal Hospital
    Saitama, Koshigaya, 343-8577, Japan
  • Dojinkinenkai Meiwa Hospital
    Tokyo, Chiyoda-ku, 101-0041, Japan
  • Tokyo Asbo Clinic
    Tokyo, Chuo-ku, 104-0031, Japan
  • Shinagawa East one Medical Clinic
    Tokyo, Minato-ku, 108-0075, Japan
  • Ikebukuro Metropolitan Clinic
    Tokyo, Toshima-ku, 171-0021, Japan
09

References and documents

Publications

  • Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K, Clark D, Yasui A, Seino Y. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021 Apr 7;11(4):e045844. doi: 10.1136/bmjopen-2020-045844. PubMed 33827843 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2022, 22 months.

Results were first posted in Mar 2024, 1 year 6 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 22 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Aug 28, 2020
StartActual
Oct 5, 2020
Primary completionActual
Aug 19, 2022
CompletionActual
Aug 26, 2022
Results first posted
Mar 12, 2024
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04531462
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Oct 5, 2020
Primary completion
Aug 19, 2022
Completion
Aug 26, 2022
Results posted
Mar 12, 2024
Last update
May 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion